These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8287644)

  • 1. Tumour necrosis factor-alpha, resting energy expenditure and cachexia in cystic fibrosis.
    Elborn JS; Cordon SM; Western PJ; Macdonald IA; Shale DJ
    Clin Sci (Lond); 1993 Nov; 85(5):563-8. PubMed ID: 8287644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic and inflammatory responses to pulmonary exacerbation in adults with cystic fibrosis.
    Bell SC; Bowerman AM; Nixon LE; Macdonald IA; Elborn JS; Shale DJ
    Eur J Clin Invest; 2000 Jun; 30(6):553-9. PubMed ID: 10849026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma tumour necrosis factor alpha in cystic fibrosis.
    Norman D; Elborn JS; Cordon SM; Rayner RJ; Wiseman MS; Hiller EJ; Shale DJ
    Thorax; 1991 Feb; 46(2):91-5. PubMed ID: 2014508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The host inflammatory response prior to death in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection.
    Elborn JS; Cordon SM; Parker D; Delamere FM; Shale DJ
    Respir Med; 1993 Nov; 87(8):603-7. PubMed ID: 8290744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of elective antibiotic therapy on resting energy expenditure and inflammation in cystic fibrosis.
    Burdet L; Hugli O; Aubert JD; Schutz Y; Roulet M; Fitting JW
    Eur J Pediatr; 1999 Sep; 158(9):711-6. PubMed ID: 10485301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating immunoreactive interleukin-6 in cystic fibrosis.
    Nixon LS; Yung B; Bell SC; Elborn JS; Shale DJ
    Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1764-9. PubMed ID: 9620903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa.
    Jones AM; Martin L; Bright-Thomas RJ; Dodd ME; McDowell A; Moffitt KL; Elborn JS; Webb AK
    Eur Respir J; 2003 Sep; 22(3):503-6. PubMed ID: 14516142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased resting energy expenditure in cystic fibrosis.
    Buchdahl RM; Cox M; Fulleylove C; Marchant JL; Tomkins AM; Brueton MJ; Warner JO
    J Appl Physiol (1985); 1988 May; 64(5):1810-6. PubMed ID: 3391885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resting energy expenditure in infants with cystic fibrosis.
    Girardet JP; Tounian P; Sardet A; Veinberg F; Grimfeld A; Tournier G; Fontaine JL
    J Pediatr Gastroenterol Nutr; 1994 Feb; 18(2):214-9. PubMed ID: 8014770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory markers in cystic fibrosis.
    Rayner RJ; Wiseman MS; Cordon SM; Norman D; Hiller EJ; Shale DJ
    Respir Med; 1991 Mar; 85(2):139-45. PubMed ID: 1887131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations.
    Stallings VA; Sainath N; Oberle M; Bertolaso C; Schall JI
    J Pediatr; 2018 Oct; 201():229-237.e4. PubMed ID: 30029855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cystic fibrosis gene and resting energy expenditure.
    Fried MD; Durie PR; Tsui LC; Corey M; Levison H; Pencharz PB
    J Pediatr; 1991 Dec; 119(6):913-6. PubMed ID: 1960606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human neutrophil elastase and elastase/alpha 1-antiprotease complex in cystic fibrosis. Comparison with interstitial lung disease and evaluation of the effect of intravenously administered antibiotic therapy.
    Meyer KC; Lewandoski JR; Zimmerman JJ; Nunley D; Calhoun WJ; Dopico GA
    Am Rev Respir Dis; 1991 Sep; 144(3 Pt 1):580-5. PubMed ID: 1892298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis.
    Balfour-Lynn IM; Klein NJ; Dinwiddie R
    Arch Dis Child; 1997 Aug; 77(2):124-30. PubMed ID: 9301350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating levels of tumor necrosis factor and interleukin-1 in cystic fibrosis.
    Brown MA; Morgan WJ; Finley PR; Scuderi P
    Pediatr Pulmonol; 1991; 10(2):86-91. PubMed ID: 2030926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma interleukin-1 alpha and beta, tumor necrosis factor-alpha, and lipopolysaccharide concentrations during pulmonary exacerbations of cystic fibrosis.
    Wilmott RW; Frenzke M; Kociela V; Peng L
    Pediatr Pulmonol; 1994 Jul; 18(1):21-7. PubMed ID: 7970903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pentoxifylline on sputum neutrophil elastase and pulmonary function in patients with cystic fibrosis: preliminary observations.
    Aronoff SC; Quinn FJ; Carpenter LS; Novick WJ
    J Pediatr; 1994 Dec; 125(6 Pt 1):992-7. PubMed ID: 7996376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resting energy expenditure and oxygen cost of breathing in patients with cystic fibrosis.
    Bell SC; Saunders MJ; Elborn JS; Shale DJ
    Thorax; 1996 Feb; 51(2):126-31. PubMed ID: 8711641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil mediators, Pseudomonas, and pulmonary dysfunction in cystic fibrosis.
    Meyer KC; Zimmerman J
    J Lab Clin Med; 1993 May; 121(5):654-61. PubMed ID: 8386737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.
    Metsios GS; Stavropoulos-Kalinoglou A; Douglas KM; Koutedakis Y; Nevill AM; Panoulas VF; Kita M; Kitas GD
    Rheumatology (Oxford); 2007 Dec; 46(12):1824-7. PubMed ID: 18032540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.